title: The potential for immunogenicity of autologous induced pluripotent stem cell-derived therapies.
abstract: Induced pluripotent stem cell (iPSC) technology offers the promise of immune-matched cell therapies for a wide range of diseases and injuries. It is generally assumed that cells derived from autologous iPSCs will be immune-privileged. However, there are reasons to question this assumption, including recent studies that have tested iPSC immunogenicity in various ways with conflicting results. Understanding the risk of an immune response and developing strategies to minimize it will be important steps before clinical testing. Here, we review the evidence for autologous iPSC immunogenicity, its potential causes, and approaches for assessment and mitigation.
authors.affiliation: From the California Institute for Regenerative Medicine, San Francisco, California 94107.
authors.forename: Zachary S
authors.initials: ZS
authors.lastname: Scheiner
authors.forename: Sohel
authors.initials: S
authors.lastname: Talib
authors.forename: Ellen G
authors.initials: EG
authors.lastname: Feigal
mesh_terms: D000818:Animals; D002986:Clinical Trials as Topic; D006801:Humans; D057026:Induced Pluripotent Stem Cells / Q000276:immunology* / Q000637:transplantation*; D033581:Stem Cell Transplantation; D014182:Transplantation, Autologous
keywords: Cell Therapy; Cellular Immune Response; Humoral Response; Induced Pluripotent Stem Cells; Innate Immunity; iPSC